Glonghui, October 21|Bank of America has raised Gilead Sciences’ target price from $168 to $172, maintaining a “Buy” rating.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.